IGHE and chronic rhinosinusitis with nasal polyps: Monoclonal antibodies (Mabs) may act on type 2 inflammatory response in several ways: by targeting the IL-5 pathways (mepolizumab or benralizumab) [12–14], neutralizing the IgE-mediated response (omalizumab) [15], and acting against IL-4 and IL-13 signaling (dupilumab) [16, 17], demonstrating, the three drugs mentioned, efficacy in the treatment of CRSwNP [18–22].